Article info

Download PDFPDF

Short report
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors

Authors

  1. Correspondence to Professor Giuseppe Lopalco; giuseppe.lopalco{at}uniba.it
View Full Text

Citation

Venerito V, Stefanizzi P, Fornaro M, et al
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors

Publication history

  • Received July 27, 2021
  • Accepted December 5, 2021
  • First published January 5, 2022.
Online issue publication 
January 05, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.